Autopsy report · NCT04217317

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

“Low accruals”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 3 years 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Relapsed T-Cell Lymphoma; Refractory T-Cell Lymphoma; Non Hodgkin Lymphoma

Interventions

CPI 613; Bendamustine

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
  “Low accrual” (97% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.